Chiasma Reports First Quarter 2020 Financial Results
May 07, 2020 16:05 ET
|
Chiasma, Inc.
NEEDHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients who face challenges...
Chiasma Enters Into Revenue Interest Financing Agreement for up to $75 Million with Healthcare Royalty Partners
April 08, 2020 07:00 ET
|
Chiasma, Inc.
NEEDHAM, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious...
Chiasma Reports Fourth Quarter and Full Year 2019 Financial Results
March 16, 2020 16:05 ET
|
Chiasma, Inc.
MYCAPSSA® PDUFA Date Set for June 26, 2020; U.S. Commercial Launch Planned in Q4’20 First Industry Sponsored U.S. Disease State Registry for Acromegaly Began Enrolling Patients NEEDHAM, Mass.,...
Chiasma To Report Fourth Quarter and Full Year 2019 Financial Results On March 16, 2020
March 09, 2020 16:05 ET
|
Chiasma, Inc.
NEEDHAM, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces FDA Acceptance of MYCAPSSA® New Drug Application Resubmission
January 13, 2020 07:00 ET
|
Chiasma, Inc.
FDA sets PDUFA date of June 26, 2020 Acceptance follows December 26, 2019 NDA resubmission NEEDHAM, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage...
Chiasma Provides Corporate Update and Previews 2020 Milestones
January 10, 2020 07:00 ET
|
Chiasma, Inc.
MYCAPSSA® NDA resubmitted to FDA; PDUFA decision expected mid-2020 MYCAPSSA® U.S. commercial launch planned for the fourth quarter of 2020 Top-line MYCAPSSA® MPOWERED Phase 3 results on track for...
Chiasma Added to NASDAQ Biotechnology Index
December 19, 2019 16:05 ET
|
Chiasma, Inc.
NEEDHAM, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma to Present at the Piper Jaffray 31st Annual Healthcare Conference
November 26, 2019 16:05 ET
|
Chiasma, Inc.
WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma to Present at the 13th Acromegaly Consensus Conference
November 14, 2019 16:05 ET
|
Chiasma, Inc.
WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Reports Third Quarter 2019 Results
November 05, 2019 16:05 ET
|
Chiasma, Inc.
CHIASMA OPTIMAL trial, conducted under SPA and designed to support FDA approval, met the primary and all secondary endpoints MYCAPSSA® NDA on track for submission by year-end 2019 MPOWEREDTM Phase 3...